Rogers Corp (ROG)

Trade ROG now with
3/21/2018 4:30:03 PM Rogers Corp. Says Janice Stipp To Retire As SVP, Finance And CFO In May
3/21/2018 12:48:49 PM FDA Approves Genentech’s Lucentis 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy
3/20/2018 1:13:26 AM Genentech: Phase III IMpower131 Study Of TECENTRIQ Plus Chemotherapy Meets Co-primary Endpoint
2/27/2018 4:10:07 PM Rogers Corp. Q4 EPS $0.37 Vs. $0.65 Year Ago
2/14/2018 1:01:26 AM FDA Grants Priority Review For Genentech’s Rituxan For Pemphigus Vulgaris
2/12/2018 1:01:27 AM Genentech Announces Encouraging Results From Phase II BOULEVARD Study
2/5/2018 5:01:53 PM Genentech Reports Results From Positive Phase III IMmotion151 Study Of TECENTRIQ And Avastin
1/8/2018 1:02:23 AM GE, Roche Enter Partnership To Develop Integrated Digital Diagnostics Platform
12/22/2017 1:02:03 AM Roche To Buy Ignyta For US$27.00/shr; Total Transaction Value Of US$1.7 Bln
12/12/2017 7:34:32 AM Genentec Says Phase III MURANO Study Results Evaluating Venclexta Plus Rituxan Compared To Bendamustine Plus Rituxan
12/11/2017 1:01:22 AM Genentech Says Phase III IMmotion151 Study Met Its Co-primary Endpoint
12/10/2017 10:46:08 AM Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan Increased CR Rates
12/7/2017 1:03:45 AM Genentech Reports Positive Interim Results From Phase III HAVEN 4 Study On HEMLIBRA (emicizumab-kxwh)
12/7/2017 1:03:34 AM Genentech Announces Results From Positive, Pivotal Phase III IMpower150 Study Of TECENTRIQ And Avastin
12/6/2017 11:21:10 AM Rogers May Dump Toronto Blue Jays
12/1/2017 10:04:04 AM Roche Supports FDA Communication About Potential For Biotin Interference With Lab Tests
11/27/2017 7:31:12 AM Roche Announces Launch Of HyperCap Target Enrichment Portfolio
11/20/2017 1:06:25 AM Genentech Says Phase III IMpower150 Study Met Its Co-primary Endpoint Of Progression-free Survival